Key Points
- CEO Helen Torley sold 20,000 Halozyme shares at an average price of $107.24, generating approximately $2.14 million. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving her with 767,780 shares.
- Halozyme reported strong quarterly results, with EPS of $2.28 versus the $1.79 consensus estimate and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
- Analysts remain broadly positive, with nine Buy ratings and an overall “Moderate Buy” consensus, although the average price target of $91.20 is below the stock’s reported $107.20 price.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the company's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,336,727.20. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00.
- On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00.
- On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $79.77, for a total value of $153,397.71.
Halozyme Therapeutics Stock Up 0.2%
Halozyme Therapeutics stock opened at $107.20 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $111.15. The firm has a market capitalization of $12.17 billion, a price-to-earnings ratio of 32.00, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88. The stock's fifty day moving average is $93.73 and its two-hundred day moving average is $76.97. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the previous year, the firm earned $1.54 EPS. The business's revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current fiscal year.
Institutional Trading of Halozyme Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Empowered Funds LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth $755,000. Acadian Asset Management LLC acquired a new position in Halozyme Therapeutics in the first quarter valued at $195,000. Hsbc Holdings PLC lifted its position in Halozyme Therapeutics by 117.1% during the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company's stock worth $522,000 after buying an additional 5,448 shares during the period. EverSource Wealth Advisors LLC lifted its position in Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock worth $140,000 after buying an additional 174 shares during the period. Finally, Baird Financial Group Inc. boosted its stake in Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company's stock worth $577,000 after buying an additional 650 shares during the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on HALO. TD Cowen upped their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a report on Friday, August 7th. Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Citizens Jmp increased their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research note on Friday, August 7th. UBS Group reiterated a "buy" rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $91.20.
Read Our Latest Research Report on Halozyme Therapeutics
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.
Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
